Resistance to Leishmania major induced by tolerance to a single antigen

Science

Volumn 274, Issue 5286, 1996, Pages 421-423

  Julia, Valérie ^a   Rassoulzadegan, Minoo ^b   Glaichenhaus, Nicolas ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5; PARASITE ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HELPER CELL; HOST RESISTANCE; IMMUNE RESPONSE; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; PARASITISM; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, PROTOZOAN; CROSSES, GENETIC; FEMALE; IMMUNE TOLERANCE; IMMUNITY, NATURAL; IMMUNIZATION; INTERLEUKIN-4; INTERLEUKIN-5; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PHENOTYPE; PROTOZOAN PROTEINS; TH1 CELLS; TH2 CELLS;

ANIMALIA; LEISHMANIA MAJOR;

EID: 0029849205     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.274.5286.421     Document Type: Article

References (39)

1. T. R. Mosmann and S. Sad, Immunol. Today 17, 138 (1996).
2. M. D. Sadick, F. P. Heinzel, V. M. Shigekane, W. L. Fisher, R. M. Locksley, J. Immunol. 139, 1303 (1987); R. P. Heinzel, M. D. Sadick, B. J. Holaday, R. L. Coffman, R. M. Locksley, J. Exp. Med. 169, 59 (1989); F. P. Heinzel, M. D. Sadick, S. S. Mutha, R. M. Locksley, Proc. Natl. Acad. Sci. U.S.A. 88, 7011 (1991); L. Morris, T. Aebisher, E. Handman, A. Kelso, Int. Immunol. 5, 761 (1993).
3. M. D. Sadick, F. P. Heinzel, V. M. Shigekane, W. L. Fisher, R. M. Locksley, J. Immunol. 139, 1303 (1987); R. P. Heinzel, M. D. Sadick, B. J. Holaday, R. L. Coffman, R. M. Locksley, J. Exp. Med. 169, 59 (1989); F. P. Heinzel, M. D. Sadick, S. S. Mutha, R. M. Locksley, Proc. Natl. Acad. Sci. U.S.A. 88, 7011 (1991); L. Morris, T. Aebisher, E. Handman, A. Kelso, Int. Immunol. 5, 761 (1993).
4. M. D. Sadick, F. P. Heinzel, V. M. Shigekane, W. L. Fisher, R. M. Locksley, J. Immunol. 139, 1303 (1987); R. P. Heinzel, M. D. Sadick, B. J. Holaday, R. L. Coffman, R. M. Locksley, J. Exp. Med. 169, 59 (1989); F. P. Heinzel, M. D. Sadick, S. S. Mutha, R. M. Locksley, Proc. Natl. Acad. Sci. U.S.A. 88, 7011 (1991); L. Morris, T. Aebisher, E. Handman, A. Kelso, Int. Immunol. 5, 761 (1993).
5. M. D. Sadick, F. P. Heinzel, V. M. Shigekane, W. L. Fisher, R. M. Locksley, J. Immunol. 139, 1303 (1987); R. P. Heinzel, M. D. Sadick, B. J. Holaday, R. L. Coffman, R. M. Locksley, J. Exp. Med. 169, 59 (1989); F. P. Heinzel, M. D. Sadick, S. S. Mutha, R. M. Locksley, Proc. Natl. Acad. Sci. U.S.A. 88, 7011 (1991); L. Morris, T. Aebisher, E. Handman, A. Kelso, Int. Immunol. 5, 761 (1993).
6. M. D. Sadick et al., J. Exp. Med. 171, 115 (1990).
7. R. A. Seder, W. E. Paul, M. M. Davis, B. Fazekas de St. Groth, ibid. 176, 1091 (1992); R. A. Seder and W. E. Paul, Annu. Rev. Immunol. 12, 635 (1994).
8. R. A. Seder, W. E. Paul, M. M. Davis, B. Fazekas de St. Groth, ibid. 176, 1091 (1992); R. A. Seder and W. E. Paul, Annu. Rev. Immunol. 12, 635 (1994).
9. S. L. Reiner, S. Zheng, Z.-E. Wang, L. Stowring, R. M. Locksley, J. Exp. Med. 179, 447 (1994).
10. A. Bendelac, N. Killeen, D. R. Littman, R. H. Schwartz, Science 263, 1774 (1994); A. Bendelac et al., ibid. 268, 863 (1995).
11. A. Bendelac, N. Killeen, D. R. Littman, R. H. Schwartz, Science 263, 1774 (1994); A. Bendelac et al., ibid. 268, 863 (1995).
12. S. Reiner, personal communication.
13. E. Mougneau et al., Science 268, 563 (1995).
14. S. L. Reiner, Z.-E. Wang, F. Hatam, P. Scott, R. Locksley, ibid. 259, 1457 (1993).
15. 6 mitomycin C-treated syngeneic splenocytes and SLA (50 μg/ml) or 30 μM LACK synthetic peptide (amino acids 158 through 173).
16. 3 cells per well) in triplicate to 96-well microtiter plates (Millipore, Bedford, MA) that had been coated with the capturing monoclonal antibodies (mAbs) (2 μg/ml), antibody to IFN-γ, antibody to IL-4, or antibody to IL-5. After 24 hours, cells were removed and spot-forming cells were visualized with biotinylated detecting mAbs and avidin D peroxidase in conjunction with 3-amino-9-ethylcarbazole (Sigma) substrate. Spots were counted under a dissecting microscope, and the frequency of antigen-specific cells was determined from the difference between the number of spots seen with and without antigen.
17. L. R. B. Soarez, E. E. Sercarz, A. Miller, Int. Immunol. 6, 785 (1994).
18. A. Campos-Neto et al., J. Exp. Med. 182, 1423 (1995).
19. 1 mouse embryos and implantation into pseudopregnant foster mothers. The IE-LACK trangenic mice studied were backcrossed eight generations to BALB/c mice and were maintained under specific pathogen-free conditions.
20. 3H]thymidine during the last 18 hours of culture. Plates were harvested and counted on a Betaplate Reader (Pharmacia, LKB). Parallel cultures were set up to measure amounts of cytokines in the supernatants by enzyme-linked immunosorbent assay, with the use of specific mAbs to IL-4, IL-5, or IFN-γ (PharMingen, San Diego, CA).
21. 1 background, we cannot completely rule out the possibility that the transgene integrated near and segregated with a resistant gene despite eight generations of backcrossing to BALB/c mice. This is, however, very unlikely to happen.
22. S. Constant, C. Pfeiffer, A. Woodard, T. Pasqualini, K. Bottomly, J. Exp. Med. 182, 1591 (1995); N. A. Hosken, K. Shibuya, A. W. Heath, K. M. Murphy, A. O'Garra, ibid., p. 1579.
23. S. Constant, C. Pfeiffer, A. Woodard, T. Pasqualini, K. Bottomly, J. Exp. Med. 182, 1591 (1995); N. A. Hosken, K. Shibuya, A. W. Heath, K. M. Murphy, A. O'Garra, ibid., p. 1579.
24. V. Kumar et al., Proc. Natl. Acad. Sci. U.S.A. 92, 9510 (1995).
25. T. F. Gajewski, M. Pinnas, T. Wong, F. W. Fitch, J. Immunol. 146, 1750 (1991); T.-L. Chang et al., ibid. 145, 2803 (1990).
26. T. F. Gajewski, M. Pinnas, T. Wong, F. W. Fitch, J. Immunol. 146, 1750 (1991); T.-L. Chang et al., ibid. 145, 2803 (1990).
27. L. Carrera et al., J. Exp. Med. 183, 515 (1996).
28. M. Roberts, B. A. Mock, J. M. Blackwell, Eur. J. Immunogenet. 20, 349 (1993).
29. A. H. Shankar and R. G. Titus, J. Exp. Med. 181, 845 (1995).
30. M. L. Güler et al., Science 271, 984 (1996).
31. J. L. Urban et al., Cell 54, 577 (1988); H. Acha-Orbea et al., ibid., p. 263.
32. J. L. Urban et al., Cell 54, 577 (1988); H. Acha-Orbea et al., ibid., p. 263.
33. A. M. Mowat, Immunol. Today 8, 93 (1987); K. L. Weiner et al., Annu. Rev. Immunol. 12, 809 (1994); R. S. Liblau et al., Proc. Natl. Acad. Sci. U.S.A. 93, 3031 (1996).
34. A. M. Mowat, Immunol. Today 8, 93 (1987); K. L. Weiner et al., Annu. Rev. Immunol. 12, 809 (1994); R. S. Liblau et al., Proc. Natl. Acad. Sci. U.S.A. 93, 3031 (1996).
35. A. M. Mowat, Immunol. Today 8, 93 (1987); K. L. Weiner et al., Annu. Rev. Immunol. 12, 809 (1994); R. S. Liblau et al., Proc. Natl. Acad. Sci. U.S.A. 93, 3031 (1996).
36. L. Morris, A. B. Troutt, E. Handman, A. Kelso, J. Immunol. 149, 2715 (1992).
37. Single-letter abbreviations for the amino acid residues are as follows; A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
38. P. Scott, E. Pearce, P. Natovitz, A. Sher, J. Immunol. 139, 3118 (1987).
39. We thank K. Marcu, S. McSorley, and E. Sercarz for reviewing this manuscript; D. Mathis, C. Benoist, and C. Gabaglia for reagents; and F. Altare for preparing the IE-LACK transgene. Supported by grants from the Conseil Régional de la Région PACA, the Special Program for Research and Training in Tropical Diseases (United Nations Development Programme-World Bank-World Health Organization), and the Ministère de l'Education Nationale, de la Recherche et de l'Enseignement Supérieur (France).